Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 215-219

  Abe, Masahiro ^a   Takiguchi, Yoshiharu ^a   Ichimaru, Satoshi ^a   Kaji, Shinichiro ^a   Tsuchiya, Koichiro ^a   Wada, Koichiro ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Bolus injection; Continuous infusion; Myocardial ischemia reperfusion injury; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

ACETYLCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; I-KAPPA B PROTEINS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NF-KAPPA B; PEROXIDASE; PHOSPHORYLATION; PPAR GAMMA; PROTECTIVE AGENTS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549086103     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.005     Document Type: Article

References (29)

1. Abdelrahman M., Sivarajah A., and Thiemermann C. Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res. 65 (2005) 772-781
2. Aruoma O.I., Halliwell B., Hoey B.M., and Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6 (1989) 593-597
3. Barnes P.J., and Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336 (1997) 1066-1071
4. Bradley P.P., Priebat D.A., Christensen R.D., and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78 (1982) 206-209
5. Chandrasekar B., Streitman J.E., Colston J.T., and Freeman G.L. Inhibition of nuclear factor κB attenuates proinflammatory cytokine and inducible nitric-oxide synthase expression in postischemic myocardium. Biochim. Biophys. Acta 1406 (1998) 91-106
6. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53 (2002) 31-47
7. Harada D., Naito S., Hiraoka I., and Otagiri M. In vivo kinetic analysis of covalent binding between N-acetyl-l-cysteine and plasma protein through the formation of mixed disulfide in rats. Pharm. Res. 19 (2002) 615-620
8. Ito H., Nakano A., Kinoshita M., and Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. 83 (2003) 1715-1721
9. Kaminski K.A., Bonda T.A., Korecki J., and Musial W.J. Oxidative stress and neutrophil activation-the two keystones of ischemia/reperfusion injury. Int. J. Cardiol. 86 (2002) 41-59
10. Khandoudi N., Delerive P., Berrebi-Bertrand I., Buckingham R.E., Staels B., and Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51 (2002) 1507-1514
11. Kuwano K., and Hara N. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family. Am. J. Respir. Cell Mol. Biol. 22 (2000) 147-149
12. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 270 (1995) 12953-12956
13. Lehrke M., and Lazar M.A. The many faces of PPARγ. Cell 123 (2005) 993-999
14. Li C., Browder W., and Kao R.L. Early activation of transcription factor NF-κB during ischemia in perfused rat heart. Am. J. Physiol. 276 (1999) H543-H552
15. Ma X.L., Tsao P.S., and Lefer A.M. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J. Clin. Invest. 88 (1991) 1237-1243
16. Mantell L.L., Horowitz S., Davis J.M., and Kazzaz J.A. Hyperoxia-induced cell death in the lung-the correlation of apoptosis, necrosis, and inflammation. Ann. N.Y. Acad. Sci. 887 (1999) 171-180
17. Morgan E.N., Boyle E.M., Yun Jr. W., Griscavage-Ennis J.M., Farr A.L., Canty Jr. T.G., Pohlman T.H., and Verrier E.D. An essential role for NF-κB in the cardioadaptive response to ischemia. Ann. Thorac. Surg 68 (1999) 377-382
18. Muzeeb S., Venkatesh P., Mullangi R., and Srinivas N.R. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica 36 (2006) 838-856
19. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., Ohnishi S., Saubermann L.J., Kadowaki T., Blumberg R.S., Nagai R., and Matsuhashi N. Endogenous PPAR γ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469
20. Pérez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvo S., Jordán J., Ceña V., and Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-γ. J. Biol. Chem. 279 (2004) 8976-8985
21. Romson J.L., Hook B.G., Kunkel S.L., Abrams G.D., Schork M.A., and Lucchesi B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67 (1983) 1016-1023
22. Tang W.H., Maroo A., and Young J.B. Ischemic heart disease and congestive heart failure in diabetic patients. Med. Clin. North Am. 88 (2004) 1037-1061
23. Taniguchi M., Uchinami M., Doi K., Yoshida M., Sasaki H., Tamagawa K., Horiuchi T., and Tanaka K. Edaravone reduces ischemia-reperfusion injury mediators in rat liver. J. Surg. Res. 137 (2007) 69-74
24. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P.K., and Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J. 16 (2002) 1027-1040
25. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., and Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J. Biol. Chem. 275 (2000) 1873-1877
26. Xu Y., Lu L., Greyson C., Lee J., Gen M., Kinugawa K., Long C.S., and Schwartz G.G. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-γ activator in myocardial ischemia and reperfusion in pigs. Diabetes 52 (2003) 1187-1194
27. Young P.W., Buckle D.R., Cantello B.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D., Hindley R.M., Holder J.C., Kallender H., Latter A.J., Lawrie K.W., Mossakowska D., Murphy G.J., Roxbee, Cox L., and Smith S.A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 284 (1998) 751-759
28. Yue Tl.TL., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., and Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104 (2001) 2588-2594
29. Zhu P., Lu L., Xu Y., and Schwartz G.G. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101 (2000) 1165-1171